<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790487</url>
  </required_header>
  <id_info>
    <org_study_id>LCH-6-072019</org_study_id>
    <nct_id>NCT04790487</nct_id>
  </id_info>
  <brief_title>Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis</brief_title>
  <official_title>A Randomized Placebo Control Trial to Evaluate the Efficacy of Chlorpheniramine Maleate Nasal Spray vs. Placebo for Acute or Chronic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcos Sanchez-Gonzalez, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larkin Community Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis is defined as the symptoms of sneezing, nasal itching, airflow obstruction,&#xD;
      and, mostly, clear nasal discharge caused by IgE-mediated reactions against inhaled allergens&#xD;
      and involving mucosal inflammation driven by T cells (Th2) auxiliary type 2. pollens and&#xD;
      molds, as well as allergens from perennial interiors, such as dust mites, pets, pests, and&#xD;
      some molds. The pattern of dominant allergens depends on the geographic region and degree of&#xD;
      urbanization, but the general prevalence of sensitization to allergens does not vary among&#xD;
      census districts in the United States. This research proposes to study a separate&#xD;
      antihistamine in a nasal spray. It is important to note that this antihistamine is available&#xD;
      without prescription (OTC) and has been studied intranasal since the 1950s1&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic rhinitis is defined as the symptoms of sneezing, nasal itching, airflow obstruction&#xD;
      and, mostly, clear nasal discharge caused by IgE-mediated reactions against inhaled allergens&#xD;
      and involving mucosal inflammation driven by T cells (Th2) auxiliary type 2. pollens and&#xD;
      molds, as well as allergens from perennial interiors, such as dust mites, pets, pests and&#xD;
      some molds. The pattern of dominant allergens depends on the geographic region and degree of&#xD;
      urbanization, but the general prevalence of sensitization to allergens does not vary among&#xD;
      census districts in the United States.2 Sensitization to inhaled allergens begins during the&#xD;
      first year of life; Sensitization to indoor allergens precedes sensitization to pollens.&#xD;
      Because viral respiratory infections occur frequently in young children and produce similar&#xD;
      symptoms, it is very difficult to diagnose allergic rhinitis in the first 2 or 3 years of&#xD;
      life. The prevalence of allergic rhinitis reaches its peak in the second to fourth decades of&#xD;
      life and then gradually decreases.&#xD;
&#xD;
      The frequency of sensitization to inhaled allergens is increasing and is now more than 40% in&#xD;
      many populations in the United States and Europe. The prevalence of allergic rhinitis in the&#xD;
      United States is approximately 30%. Allergic rhinitis contributes to lost or unproductive&#xD;
      time at work and school, to sleep problems and among affected children, to less participation&#xD;
      in outdoor activities. In addition, children with allergic rhinitis are more likely than&#xD;
      unaffected children to have myringotomy tubes placed and their tonsils and adenoids removed.&#xD;
      The ability to control asthma in people with asthma and allergic rhinitis has been linked to&#xD;
      the control of allergic rhinitis.&#xD;
&#xD;
      Most people with asthma have rhinitis. The presence of allergic rhinitis (seasonal or&#xD;
      perennial) significantly increases the likelihood of asthma: up to 40% of people with&#xD;
      allergic rhinitis have or will have asthma. It is also important to define the physiological&#xD;
      functional breathing of obstructive sleep apnea (OSA). Functional or physiological breathing&#xD;
      is through the nose, while OSA is the collapse of the muscles of the oropharyngeal airways.&#xD;
      Nasal obstruction and OSA are usually comorbid. Therapies to increase nasal volume and&#xD;
      airflow in compromised patients have a significant benefit in reducing the symptoms of&#xD;
      nighttime and daytime respiratory disorders.&#xD;
&#xD;
      The nose represents more than 50% of the total resistance of the upper airway and plays an&#xD;
      important role in the establishment of physiological functions such as humidification,&#xD;
      heating and air filtration. The nasal mucosa is a dynamic organ controlled by the autonomic&#xD;
      nervous system. Periodic nasal congestion and decongestion have been termed the &quot;nasal&#xD;
      cycle.&quot; In patients with permanent unilateral nasal obstruction, the nasal cycle can&#xD;
      contribute to a significant increase in total resistance of the respiratory tract.&#xD;
&#xD;
      Each nasal inhalation mixes nitric oxide (NO) gas from the maxillary sinuses and is&#xD;
      transported to the lungs. It is NOT necessary for the movement of the cilia in the paranasal&#xD;
      sinuses to carry out the waste, it is anti-fungal, antibacterial and anti-viral, it is also&#xD;
      important in the peripheral vasodilatation of the blood vessels. In selected patients, it was&#xD;
      recommended that the final point to treat OSA be the restoration of nasal breathing.&#xD;
      Resistance of the upper respiratory tract can cause an increase in blood pressure. Mouth&#xD;
      breathing does not have any of the mechanisms of physiological protection, so that people&#xD;
      with this condition are more prone to respiratory infections, as well as to dental sequelae&#xD;
      (gum disease, open anterior bite). That is why the investigators propose to study the&#xD;
      combination of an antihistamine with more than 60 years in the market that was studied&#xD;
      intranasal in the 50s. Nowadays it is known that the combination of antihistamine have better&#xD;
      effect, less side effects than oral treatments. In the US and Europe, a combination of&#xD;
      steroids with antihistamine of European origin is available only by recipes and is highly&#xD;
      expensive. This research proposes to study a separate antihistamine in a nasal spray. It is&#xD;
      important to note that this antihistamine is available without prescription (OTC) and has&#xD;
      been studied intranasal since the 1950s1,2.&#xD;
&#xD;
      Method&#xD;
&#xD;
      A multicenter, randomized, double-blind, 14-day study will be conducted during the spring of&#xD;
      2019. After starting 5 days of placebo therapy, 100 patients from each group with moderate to&#xD;
      severe nasal symptoms will be randomized to treatment. with (1) chlorpheniramine nasal spray&#xD;
      vs placebo (nasal saline). All treatments will be administered in the form of 1 spray per&#xD;
      nostril twice a day. The main variable of effectiveness will be the change from the beginning&#xD;
      in the total score of nasal symptoms (TNSS), which consists of nasal congestion, nasal&#xD;
      discharge, nasal itching and sneezing. The main efficacy variables will be (1) the change&#xD;
      from the beginning to day 14 in the total reflective nasal symptom score (TNSS) in the first&#xD;
      12 hours, which combines scores for rhinorrhea, sneezing, itchy nose and nasal congestion,&#xD;
      and (2) Start of Action, based on the instant TNSS for 4 hours after the first dose of the&#xD;
      study drug. During the double-blind treatment period, patients will record their symptom&#xD;
      scores on daily cards twice a day (morning and afternoon). Patients older than or equal to 18&#xD;
      years will complete the questionnaire on the quality of life of rhinoconjunctivitis (RQLQ) at&#xD;
      the beginning of the study and on day 14. Patients will be instructed to call the office at&#xD;
      any time for any questions . Follow-up appointments will be in 1 week, two, and four weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups placebo control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Symptom Score (DSS)</measure>
    <time_frame>30 days</time_frame>
    <description>Allergy daily symptoms score The daily symptom score (DSS) consists of six individual symptom scores: four nasal symptoms (runny nose, blocked nose, sneezing, and itchy nose) and two ocular symptoms (gritty feeling or red or itchy eyes, and watery eyes). 0 to 3: 0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; and 3 = severe symptoms for a max of 18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>30 days</time_frame>
    <description>visual analogue scale is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. The scale goes from 0 (no symptoms) to 10 (most severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Nasal Congestion</condition>
  <arm_group>
    <arm_group_label>Chlorpheniramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorpheniramine (CPM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPM</intervention_name>
    <description>one spray dose (~100 ÂµL of the solution containing 1.25 mg CPM) per nostril twice a day</description>
    <arm_group_label>Chlorpheniramine</arm_group_label>
    <other_name>Chlorpheniramine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>PLB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. No oral steroids&#xD;
&#xD;
          2. No oral antihistamine&#xD;
&#xD;
          3. No Nafasoline If the patient needs rescue treatment, he will go to the intervention&#xD;
             arm with chlorpheniramine or with the combination of chlorpheniramine and fluticasone.&#xD;
             If a participant experienced a severe acute nasal block, the investigator could&#xD;
             authorize the use of a short course of oxymetazoline spray for a maximum of 3 days and&#xD;
             a maximum total of 1 day during the treatment period. Oxymetazoline should not be used&#xD;
             within 24 hours of a scheduled visit during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Large (grade 3) polyps, indicating severe nasal obstruction&#xD;
&#xD;
          2. Surgical treatment for nasal polyps during the last 3 months&#xD;
&#xD;
          3. Cystic fibrosis&#xD;
&#xD;
          4. Purulent nasal infection&#xD;
&#xD;
          5. Allergic rhinitis&#xD;
&#xD;
          6. Any disease likely to interfere with the study parameters or which gave evidence of&#xD;
             any serious or unstable concurrent disease or psychological disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos A Sanchez-Gonzalez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Larkin Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Larkin Health System</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Van Toor BS, Buchwald A, Stengele E, Trenk D, Gercek C, de Mey CM. Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. Int J Clin Pharmacol Ther. 2001 Apr;39(4):173-8.</citation>
    <PMID>11332874</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>April 24, 2021</last_update_submitted>
  <last_update_submitted_qc>April 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Larkin Community Hospital</investigator_affiliation>
    <investigator_full_name>Marcos Sanchez-Gonzalez, MD, PhD</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <keyword>Nasal Spray</keyword>
  <keyword>Chlorpheniramine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorpheniramine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

